Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time‐to‐event endpoints

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0258|34|11|1889-1903

ISSN： 0277-6715

Source： STATISTICS IN MEDICINE, Vol.34, Iss.11, 2015-05, pp. : 1889-1903

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bayesian sample sizes for exploratory clinical trials comparing multiple experimental treatments with a control

By  

STATISTICS IN MEDICINE, Vol. 34, Iss. 12, 2015-05 ,pp. : 2048-2061

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Bayesian dose‐finding design for phase I/II clinical trials with nonignorable dropouts

By  

STATISTICS IN MEDICINE, Vol. 34, Iss. 10, 2015-05 ,pp. : 1721-1732

John Wiley & Sons Inc

Access to resources Recommend Favorite

Optimal treatment allocation for placebo‐treatment comparisons in trials with discrete‐time survival endpoints

By  

STATISTICS IN MEDICINE, Vol. 34, Iss. 27, 2015-11 ,pp. : 3490-3502

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II Multiple Linear Regression Profile with Small Sample Sizes

By  

QUALITY AND RELIABILITY ENGINEERING INTERNATIONAL, Vol. 31, Iss. 5, 2015-07 ,pp. : 851-861

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bayesian optimal interval designs for phase I clinical trials

By  

JOURNAL OF THE ROYAL STATISTICAL SOCIETY: SERIES C (APPLIED STATISTICS), Vol. 64, Iss. 3, 2015-04 ,pp. : 507-523

John Wiley & Sons Inc

Access to resources Recommend Favorite